BackZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) Overview
ZyVersa Therapeutics Inc - Units (1 Ord Share Class A & 3/4 War)

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) Return on Equity

Latest ROE for ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War): 173.38% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

ROE

173.38%

Return on Equity

173.38%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) (LSPRU) FAQ

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) posts a ROE of 173.38%. That is above the sector sector average of -6.13%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For its sector stocks, a ROE near -6.13% is typical. ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s 173.38% is higher that level. That is roughly 2929.2% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 173.38%; use YoY and peer views to separate noise from signal.

Context for LSPRU's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average -6.13%), and (3) consistency with growth and profitability. This page covers the first two; ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s other metric pages and overview cover the third.